This website is partially compliant with The European Accessibility Act. The accessibility icon on this website provides accessibility support. We can provide an accessible version of any documents/links on request if required via [email protected] ••• Be Fraud Aware: By staying vigilant, you can help yourself from being the victim of fraud.

Back

Overview Wealth Planning Service Discretionary Investment Service Other Investment Services
Overview Investment Solutions Pension Solutions SDIO Application Forms – Intermediaries
Overview

Cantor Fitzgerald Asset Management

Overview Market Updates Useful Forms Sustainability Disclosures
Fund Centre

Multi-Asset Funds

Overview Multi-Asset 70 Fund Multi-Asset 50 Fund Multi-Asset 30 Fund Balanced Fund

Equity Funds

Overview Irish Equity Fund Global Equity Fund Global Equity UCITS Fund Global Equity Income Fund

ESG/Ethical Funds

Overview Green Effects Fund Paris Aligned Global Equity Fund Ethical Fund Ethical Global Equity Fund

Thematic Funds

Overview Technology Fund Infrastructure Impact Fund New Haven Housing Fund

Alternative Investment Fund

Alternative Investment Fund (RIAIF)

Fixed Income & Cash Funds

Overview Cash Fund Long Bond Fund Fixed Interest Fund
Overview

Corporate

Overview

Real Estate

Overview Capital Markets & Advisory

Credit Unions

Overview Investment Advisory Services
Debt Capital Markets Probate Services
Dedicated to institutional wealth, stakeholder value, and a sustainable future

Dedicated to institutional wealth, stakeholder value, and a sustainable future

Overview Investment Services Stewardship
Supportive of you, your custodial 
vision, and your philanthropic goals

Supportive of you, your custodial 
vision, and your philanthropic goals

Daily Note 15/12/2022 – Market View: Day Ahead, Macro, Stocks, Debt Markets

15.12.2022



  • Markets were in a wait and see mode ahead of last night’s interest rate decision from the US Federal Reserve.
  • In an incremental positive for Sanofi, Dupixent has been approved by the EC as the first and only targeted medicine indicated for prurigo nodularis, a chronic extremely itchy skin disorder. It is already approved for the condition in the US.
  • US bond yields moved marginally higher yesterday.